The hematopoietic niche in MDS: from concept to therapeutic target
EHA Library. Raaijmakers M. Jun 15, 2018; 219077 Topic: 8Aa Hematopoiesis and stem cell biology
Dr. Marc Raaijmakers
Dr. Marc Raaijmakers
Contributions
Learning Objectives
THIS MANUSCRIPT IS PUBLISHED AS AN OFFICIAL SUPPLEMENT OF HEMASPHERE.

Eva Hellström Lindberg - Chair Introduction
This educational session on myelodysplastic syndromes aims to cover recent breakthroughs in the understanding of disease pathogenesis, the role of molecular genetics in prognosis and clinical decision-making, and how novel treatment options are developed to meet the major therapeutic gaps for patients with MDS. Dr. Raaijmakers will review mechanisms of microenvironmental contributions to disease initiation and progression, including their interplay with the malignant MDS clone. Dr. Cazzola will describe the current view of the mutational landscape of MDS and how chromosomal abnormalities and discrete gene rearrangements can be used to characterize and prognosticate more than 90% of patients with MDS. Oncogenic driver mutations include genes involved in RNA splicing, DNA methylation, chromatin modification, transcription regulation, DNA repair, signal transduction, and the cohesin complex. Dr. Platzbecker will review the pipeline of novel drugs and their potential to contribute to patient outcome. The activin receptor fusion protein luspatercept has a substantial potential to target the anemia of patients with lower-risk MDS with ring sideroblasts and presence of splice factor SF3B1 mutations. By contrast, novel therapeutic options for higher-risk MDS are still limited.
In conclusion, the session will explain how current knowledge about the clonal MDS cells and their microenvironment can be used to design and develop novel targeted treatment for specific MDS subgroups.

Learning Objectives of the article
- Disease mechanisms in MDS are complex and involve the interplay between the malignant stem cells and the bone marrow microenvironment.
- Mutation profiling is an essential component in the routine work-up of MDS including risk assessment and prediction of response to therapy.
- Luspatercept is a novel therapeutic option for patients with MDS with ringsideroblasts and anemia.

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies